Proteomics Ends Deal with US Distributor for Kidney Disease Test Kit
Proteomics International Laboratories (ASX:PIQ) issued a notice of termination to Sonic Healthcare USA, the US distributor of its diabetic kidney disease test PromarkerD, effective Tuesday, after not meeting certain milestones to commercialize the test kit, according to a Wednesday filing with the Australian bourse.
Following the termination, the diagnostic firm will now market and sell PromarkerD in the US via licensing deals with service providers, pathology laboratories, and/or direct-to-consumer/patient channels, the filing said.
The company will establish a code-compliant third-party reference laboratory ahead of the test kit's launch, the filing stated.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.